Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
City of Hope, Duarte, California Los Angeles Cancer Network, Los Angeles, California UCLA Medical Center of Hematology/Oncology, Los Angeles, California Innovative Clinical Research Institute, Whittier, California ASCLEPES Research Centers, Weeki Wachee, Florida University of Illinois at Chicago Cancer Center, Chicago, Illinois Norton Cancer Institute, Louisville, Kentucky Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska Gabrail Cancer Center Research,, Canton, Ohio Baptist Clinical Research Institute, Memphis, Tennessee University of Texas(UT) Southwestern-Children's Medical Center, Dallas, Texas